AXDX
Accelerate Diagnostics
–
Index: NASDAQ; Sector: Technology; Industry: Scientific & Technical Instr.;
Marketcap: 614.84M; Volume: 19.55K; AvgVol 3m: 367.18K; Beta: 2.54;
Cost estimate:
P/E: –; EPS: -1.50; EPS growth quarter/prev quarter: 9.20%;
EPS growth this year: 4.60%; EPS growth past 5 years: -16.90%;
EPS ttm: -1.50;
P/S: 58.33; P/B: ; P/Cashflow: 6.71; P/FCF: ;
Sales: 10.20M; Sales growth quarter/prev quarter: 16.70%; Sales growth past 5 years: 137.90%;
Profitability:
Gross Margin: 45.80%; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -63.70%; ROE – return on equity: 576.70%; LT Debt/Equity: ; Total Debt/Equity: ;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 40.66%; Insider Transactions:11.39%;
Institutional Ownership: 52.40%; Institutional Transactions: -2.91%;
Data update: 07.10.2020.